Prevalence, incidence and mortality of inflammatory bowel disease in Catalonia. A population-based analysis

Brunet, E; Roig-Ramos, Cristina; Vela, Emili; Clèries, Montserrat; Melcarne, Luigi; Villòria, Albert; Pontes, Caridad; Calvo, Xavier Calvet

doi:10.1080/07853890.2018.1523550

Cited by 19 publications

(24 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In previous studies, it is still controversial whether IBD increases mortality[53-55]. However, after adjusting for age, sex, place of residence, income, comorbidities and medication use, we demonstrated that overall mortality was 2.79-fold higher in the CD cohort and 1.98-fold higher in the UC cohort compared to the control groups.…”

Section: Discussionmentioning

confidence: 49%

Increased end-stage renal disease risk in patients with inflammatory bowel disease: A nationwide population-based study

Park

Chun

Han

et al. 2018

WJG

View full text Add to dashboard Cite

AIMTo estimate the risk of end-stage renal disease (ESRD) in patients with inflammatory bowel disease (IBD).METHODSFrom January 2010 to December 2013, patients with Crohn’s disease (CD) and ulcerative colitis (UC) were identified, based on both the International Classification of Diseases, 10th revision (ICD-10) and the rare, intractable disease registration program codes from the National Health Insurance (NHI) database in South Korea. We compared 38812 patients with IBD to age- and sex-matched non-IBD controls with a ratio of 1:3. Patients newly diagnosed with ESRD were identified with the ICD-10 code.RESULTSDuring a mean follow-up of 4.9 years, ESRD was detected in 79 (0.2%) patients with IBD and 166 (0.1%) controls. The incidence of ESRD in patients with IBD was 0.42 per 1000 person-years. Patients with IBD had a significantly higher risk of ESRD than controls [adjusted hazard ratio (HR) = 3.03; 95% confidence interval (CI): 1.77-5.20; P < 0.001]. The incidences (per 1000 person-years) of ESRD were 0.51 in patients with CD and 0.13 in controls, respectively (adjusted HR = 6.33; 95%CI: 2.75-14.56; P < 0.001). In contrast, the incidence of ESRD was similar between the UC and control groups (0.37 vs 0.37 per 1000 person-years; adjusted HR = 2.01; 95%CI: 0.90-4.51; P = 0.089).CONCLUSIONThe risk of ESRD was elevated in patients with CD, but not UC. Patients with CD should be monitored carefully for signs of renal insufficiency.

show abstract

Section: Discussionmentioning

confidence: 49%

Increased end-stage renal disease risk in patients with inflammatory bowel disease: A nationwide population-based study

Park

Chun

Han

et al. 2018

WJG

View full text Add to dashboard Cite

show abstract

“…Baseline characteristics of the patients have been described in detail in a previous article [ 17 ].…”

Section: Resultsmentioning

confidence: 99%

“…Although the rate of CD-related hospitalizations decreased from 92.7 per 1000 patients/year in 2011 to 72.2 in 2017, the total hospitalization rates showed a slight increase. In addition, annual rates per 100,000 inhabitants of CD-related hospitalization rose from 10.6 in 2011 to 14.08 per 100,000 inhabitants/year in 2017, mainly due to the near doubling of the prevalence of the disease [ 17 ]. These figures are lower than those presented by King et al in a worldwide study using the OECD database (Organization for Economic Co-operation and Development), which reported an increase for CD-related hospitalization in Spain with an average annual rate of 23.8 per 100,000 inhabitants/year in the years 2010 to 2015 [ 34 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Time Trends of Crohn’s Disease in Catalonia from 2011 to 2017. Increasing Use of Biologics Correlates with a Reduced Need for Surgery

Brunet

Vela

Melcarne³

et al. 2020

JCM

Self Cite

View full text Add to dashboard Cite

Background and Aims: Data from clinical trials suggest that biological drugs may improve the outcomes in Crohn’s disease (CD) by reducing the need for surgery or hospitalization. The aim of this study is to evaluate the time-trends of the use of biological drugs and other treatments for CD, and its relationship with outcomes in Catalonia. Materials and Methods: All patients with CD included in the Catalan Health Surveillance System (containing data on a population of more than 7.5 million) from 2011 to 2017 were identified. The exposures to different treatments for inflammatory bowel disease were retrieved from electronic invoicing records. Results: Between 2011 and 2017, the use of salicylates, corticosteroids and immunosuppressive treatment fell from 28.8% to 17.1%, 15.8% to 13.7%, and 32.9% to 29.6%, respectively (p < 0.001). Biological treatment use rose from 15.0% to 18.7% (p < 0.001). Ostomy rates per 1000 patients/year fell from 13.2 in 2011 to 9.8 in 2017 (p = 0.003), and surgical resection rates from 24.1 to 18.0 (p < 0.001). The rate of CD-related hospitalizations per 1000 patients/year also fell, from 92.7 to 72.2 (p < 0.001). Conclusions: Biological drug use rose from 15.0% to 18.7% between 2011 and 2017. During this period, we observed an improvement in the outcomes of CD patients.

show abstract

“…Moreover, as this information is used for provider payment purposes, external audits are carried out periodically to ensure the quality and reliability of the data. Hence, the CHSS provides carefully monitored population-based health data on the morbidity and mortality of more than 7.5 million people in Southern Europe, and it has been used previously for several research studies [10][11][12][13] .…”

Section: Data Source and Study Populationmentioning

confidence: 99%

Postoperative mortality after surgery for inflammatory bowel disease in the era of biological agents: A population-based study in Southern Europe

Guasch

Vela

Mañosa

et al. 2021

Digestive and Liver Disease

Self Cite

View full text Add to dashboard Cite

Prevalence, incidence and mortality of inflammatory bowel disease in Catalonia. A population-based analysis

Cited by 19 publications

References 19 publications

Increased end-stage renal disease risk in patients with inflammatory bowel disease: A nationwide population-based study

Increased end-stage renal disease risk in patients with inflammatory bowel disease: A nationwide population-based study

Time Trends of Crohn’s Disease in Catalonia from 2011 to 2017. Increasing Use of Biologics Correlates with a Reduced Need for Surgery

Postoperative mortality after surgery for inflammatory bowel disease in the era of biological agents: A population-based study in Southern Europe

Contact Info

Product

Resources

About